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ABSTRACT 
Huntington's disease (HD) is a devastating autosomal dominantly inherited neurological disorder 
caused by an abnormal expansion of CAG trinucleotide repeats in the gene coding for the N-
terminal region of the huntingtin (Htt) protein, which leads to the formation of a polyglutamine 
stretch. The greater the CAG repeats, the earlier the onset of the disease. The polyglutamine 
stretch destabilizes the Htt protein leading to misfolding, abnormal processing, aggregation, and 
inclusion formation. Mutant Htt protein is believed to damage and kill neurons in the striatum by 
a mechanism involving increased oxidative and metabolic stress, and impaired adaptive cellular 
stress responses. A large number of abnormalities have been reported in HD, including 
transcription deficits, energy impairment, excitotoxicity, and lack of trophic support.  Reduced 
trophic support contributes importantly to striatal degeneration in human HD. Specifically, brain-
derived neurotrophic factor (BDNF) expression is reduced in patients with HD. BDNF is also 
decreased in brain tissue from mice transgenic for mutant Htt. BDNF levels influences the onset 
and the severity of motor dysfunction in HD mice. In addition to BDNF, levels of the molecular 
chaperones heat shock proteins (Hsp40 and 70) decrease progressively in HD brain.  Hsp70 is a 
highly stress-inducible member of a chaperone family of proteins that functions to prevent 
misfolding and aggregation of newly synthesized mutant proteins and stress-denatured proteins. 
Hsps appear to play a critical role in HD since expression of active heat shock factor HSF1, a 
transcription factor responsible for the induction of Hsps, markedly reduces polyglutamine 
aggregate formation in both cell and mouse models.  
Many efforts have been made to develop preventive treatments for HD because of the strong 
genetic link and a freely available genetic test to identify individuals at risk. At present, only 
symptomatic therapy is available and effective therapeutic approaches to slow the disease 
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process have yet to be developed. Previous studies have shown that electroconvulsive shock 
(ECS) induces the production of growth factors including BDNF and the molecular chaperones 
HSP40 and HSP70.   Because ECS can stimulate the production of neuroprotective proteins, we 
determined whether ECS treatment could slow the progressive nature of the disease process and 
provide a therapeutic benefit in a mouse model of HD. ECS or sham treatment was administered 
to male N171-82Q Htt mutant mice. End points measured included motor function, striatal and 
cortical pathology, and levels of neurotrophic factors, protein chaperones, and proteins involved 
in synaptic plasticity. ECS treatment delayed the onset of motor symptoms, reduced body weight 
loss and extended the survival of HD mice. Striatal neurodegeneration was attenuated and levels 
of neurotrophic factors, protein chaperones and mitochondria-stabilizing protein were elevated in 
striatal cells of ECS-treated compared to sham-treated HD mice. Our findings suggest that ECS 
can increase the resistance of neurons to mutant huntingtin resulting in improved functional 
outcome and extended survival. The potential of ECS as a treatment for HD patients merits 
further consideration. 
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CHAPTER 1. INTRODUCTION 
1.1 Huntington’s Disease  
 
American doctor George Huntington first described this neurological disorder in 1872. 
Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disorder. It 
is caused by an abnormal expansion of the CAG repeat region in the exon 1 of HD gene (IT 15).  
The CAG repeats result in a polyglutamine tract which encodes the huntingtin (Htt) protein (Fig 
1). Htt is ubiquitously present in the body and the brain, but the accumulation of the mutant 
protein causes neuropathological changes therefore specifically affecting the brain (1).  
The hallmark of HD is the degeneration of the striatal tissue (2,3). The gain of function mutant 
protein is toxic and causes impairment in the normal functioning of the Htt protein. The mutant 
Htt protein is cleaved which leads to the production of toxic polyglutamine tracts. The N-
terminal polyglutamine is considered to be the cause of the toxicity by the mutant protein. The 
neuropathological damage in HD is expected to be due to the death of the striatal neurons.  The 
precise mechanism underlying the degeneration of the striatal neurons in HD is still being 
investigated. Mutant Htt causes mitochondrial dysfunction which leads to calcium imbalances. 
The energetics and dynamics of the mitochondria are affected which lead to neuronal cell death 
(4). Impairment of the ubiquitin proteasome system and also axonal transport could be another 
cause of the neuronal loss / death. Transcriptional dysregulation has been widely considered as 
one of the causes of the striatal degeneration in HD. The transcriptional dysregulation of genes 
leads to the altered expression of various neuroprotective proteins in HD and is expected to play 
a key role in the specific loss of the tissue in HD (5,6,7,8).  
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Figure 1 CAG repeats results in a polyglutamine tract which encodes Htt Protein 
 
HD is characterized by the motor and cognitive disturbances. The motor abnormalities are 
chorea, ataxia and uncoordinated movements. Chorea is expected to be caused due to neuronal 
dysfunction and motor impairment by the neuronal loss.  The striatal pathology correlates with 
the severity of motor and cognitive dysfunction. This implies that the striatal degeneration is the 
main cause of the disease process but other structures such as the cortex and the hippocampus 
are also affected by mutant Htt (9). The complexity of the disease arises from the interplay 
between these regions and these interactions play an important role in the pathology of HD 
(2,6,10).  
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1.2 Anatomy  
 
The cerebrum contains the basal ganglia which contains different nuclei. The basal ganglion is 
involved in the motor control. The basal ganglia comprises of Striatum, Globus pallidus, 
Subthalamic nuclei and Substantia nigra (Fig 2A). The basal ganglia circuitry involves a number 
of parallel loops which control and modulate the cortical outputs. Striatum is the major receptive 
component of the basal ganglia and it has three nuclei namely caudate, putamen and accumbens. 
Caudate nucleus of the striatum degenerates first followed by putamen and then nucleus 
accumbens in the later stages of the disease (12). Striatum is involved in regulating the motor 
activities. It also involved in the non motor behaviors such as cognition, attention and motivation 
(12). 
The neurotransmitters present in the straitum are inhibitory, namely GABAergic (Gamma-
aminobutyric acid). Almost 90% of the striatal neurons are medium spiny neurons which express 
GABA and about 10% are interneurons. The medium spiny neurons are further classified 
depending on the different neuropeptides. The two main classes are enkephalin-containing 
neurons and substance P containing neurons. Dopamine receptors are also widely expressed in 
the striatum. Since the striatum functions primarily in the regulation of movements and 
organization of motor activity it has a number of synaptic inputs from the cortex, midbrain and 
thalamus. Cortico-striatal neurons and thalamo-striatal inputs are excitatory since they are 
glutaminergic. Afferent from substantia nigra and ventral tegmental area are dopaminergic. The 
medium spiny neurons give rise to GABAergic efferents, which includes enkaphalinergic 
projections to lateral globus pallidus (11,12).   
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1.3 Genetics  
 
HD is due to the defect in the exon 1 of the HD gene (IT 15) on the chromosome 4. The gene for 
HD was identified in 1993 by the HD collaborative research group (9,13). The abnormal 
expansion of CAG trinucleotide is genetically unstable. It is susceptible to expansion and occurs 
within the coding region of the gene. The gene is 17 codons downstream of the initiator codon 
ATG in exon 1, where CAG codes for glutamine.   
 Normally the HD gene contains repeats in the range of 17-20. The repeats between  27-35 are 
rare, and more than 36 may cause the disease. The higher the number of repeats the more an 
individual is prone to HD. Therefore the number of repeats is inversely related to the age of onset 
of the disease. The repeats between 27-35 are meiotically unstable and can expand (13), when 
transmitted through the paternal line, thus predisposing the individual to HD at an earlier age. 
The adult onset of the disease is due to 40-50 CAG repeats and the juvenile form of the disease is 
seen when the individual has 50 or more repeats. Incomplete penetrance is generally observed in 
individuals expressing 36-41 repeats. Homozygosity is associated with a more aggressive disease 
course (9,13,14). 
Offspring of an HD parent have a 50% chance of inheriting the disease. The genetic abnormality 
equally affects both the genders and the repeats are seen in every generation. The CAG repeat 
length is a measure of the genetic testing for HD in the IT15 gene. An individual is classified as 
affected if the CAG repeat length is 39, termed as ‘pathologically fully penetrant’ (14,74).  
 
 
5 
 
1.4 Huntingtin Protein 
 
The protein encoded by the IT15 gene is Htt which has the poly Q tract. It is a 350 kD protein 
which is expressed ubiquitously in the body. The function of normal Htt in neurons is unknown, 
although it may play a role in synaptic transmission. The Htt protein is about 3144 amino acid 
long and most of it is in the cytoplasm. Along with many other functions its being speculated that 
it is involved in transcriptional regulation. The pathogenic action of mutant Htt may result from 
gain of function (Fig 1)  rather than loss of function because Htt deficient mice die early in 
embryonic development (8), while Htt +/- mice exhibit no or few neurological abnormalities 
(8,16).  Htt is widely expressed in neuron throughout the brain and it remains unclear why 
striatal medium spiny neurons are particularly vulnerable to mutant Htt. However in vulnerable 
neurons mutant Htt forms intranuclear inclusions and a similar protein aggregation process 
occurs when mutant Htt is expressed in cultured cells and transgenic mice. 
The Htt protein contains the HEAT (huntingtin, elongation factor 3, the PR65/A subunit of 
protein phosphatase 2A and lipid kinase Tor) repeat sequences (Fig 4). There are 28-36 HEAT 
repeats in the Htt protein and each HEAT repeat comprises of approximately 50 degenerate 
amino acid sequences (16). These repeats have an increased helical content and form 
superhelical structures with hydrophobic cores. HEAT repeats are present in proteins involved in 
microtubule dynamics suggesting that these repeats play an important role in protein-protein 
interaction (13,93). Structural studies reveal the structure of Htt as an elongated superhelical 
solenoid with a diameter of ~200Å (15,16). The N-terminus of the protein contains a 17 amino 
acid sequence which is involved in the interaction of the protein with intracellular membrane 
bound organelles, such as the mitochondria, golgi apparatus and endoplasmic reticulum.  
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Figure 2  The Htt protein contains the HEAT repeat sequences  
 
1.5 Transgenic mouse models of HD 
 
Transgenic mouse models have become a necessity in studying various disease processes 
(17,24). To study the neurological disease the mouse models should be robust and have limited 
variability. Along with a few other criteria they should be similar to the human disease process 
with minimum discrepancies and should display the neurobehavioral abnormalities observed in 
affected individuals (18,20). 
 The mouse models being used to study HD fall into three broad categories. The first mouse 
models are the mice which express the fragments which include the first one / two exons. The 
second are the transgenic mice which express the full length human HD gene and the third are 
the knock in mice which have the pathogenic CAG repeats. The mouse models expressing the 
poly Q fragments of the mutant Htt are similar to human HD. (19, 20). Then mouse models show 
similarities too at the molecular and are neuropathologically similar to human HD. The 
‘genetically accurate’ models do not exhibit the HD phenotype explicitly (20). 
The first transgenic model developed was the R6/2 mouse model which contains the small N-
terminal fragment of the exon 1 of the Htt protein. It has about 150 CAG repeats which give it a 
progressive phenotype. The model exhibits many of the behavioral and neuropathological 
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features of HD, but at the same time it has an excessive mutant Htt aggregate formation 
compared to human HD. On the contrary the neuronal loss is less compared to human HD and 
mice are resistant to excitotoxicity (20, 21).  
The N-171-82Q mouse model expresses a small N-terminal fragment (exon 1) of htt with ~82 
CAG repeats under prion promoter. These mice show neuropathological similarities to the 
human HD and are extensively used to test various therapies for treating HD (20,21). These mice 
exhibit a robust phenotype, rapid disease onset and progression, well defined neurobehavioural 
abnormalities that can be quantified and neuropathological changes that accurately mirror human 
HD (151). Furthermore these mice exhibit a well-characterized progressive phenotype with 
moderate variability such that experimental groups can contain as few as 10 mice and provide 
the power to detect 10% differences in many outcome measures.  
Transgenic mice with full length Htt containing 48-89 CAG repeats have been produced. They 
show behavioral abnormalities like the human HD. A yeast artificial chromosome model 
(YAC128) has been shown to have cortico-striatal loss of neurons which lead to the behavioral 
abnormalities resembling human HD. The disadvantage of these mice is that there is variability 
among them and the time of phenotype development is delayed. Hence these mice are best suited 
for therapeutic trials (20). The transgenic mice developed with the Bacterial artificial 
chromosome (BAC) have 226 poly Q repeats and full length human huntingtin gene. The 
cortico–striatal neuronal loss is not specific as human HD (20, 21, 22). 
Knock in mice are another set of genetically modified mice produced to test for HD 
pathogenesis. There have been 72-111 poly Q repeats been inserted in the mouse models and the 
behavioral and pathological phenotypes have been studied (22, 23, 24). 
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CHAPTER 2. LITERATURE REVIEW 
2.1 Transcriptional dysregulation 
 
2.1.1 Cyclic-AMP-response element-binding protein 
 
 Mutant Htt in HD samples have shown to form inclusions in the nuclei and neuritis of multiple 
neuronal populations (25,75). Full length mutant Htt or its fragments probably bind to the 
transcriptional factors which result in the regulation of gene transcription (30).  Mutant and wild 
type Htt have been shown to be involved with a number of transcription factors, one of them 
being Cyclic-AMP-response element-binding protein (CREB) binding protein (CBP) (Fig 5A,B) 
(26,75). 
CBP is present in the nucleus in normal cells, but CREB function is affected in a HD brain (31). 
There is interaction between mutant Htt and CBP, where the nuclear inclusions have been shown 
to interact with the transcriptional machinery thus causing toxicity. CBP has an acetyltransferase 
domain which acts as a coactivator for CREB-mediated transcription. The mutant Htt has been 
shown to bind with the acetyltransferase domain of CBP. This reduces the acetylation of histone 
(H3 and H4) by CBP. Histone deacetylase (HDAC) inhibitors can reverse this process, and 
improve the motor deficits in HD transgenic mouse models. The survival of HD-171-82Q mice 
is extended due to increase expression of protective proteins (13, 30, 75). 
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B 
Figure 3 Mutant and wild type Htt have been shown to be involved with a number of transcription factors, 
one of them being Cyclic-AMP-response element-binding protein (CREB) binding protein (CBP) 
A Wild type Htt have been shown to be involved with a number of transcription factors with 
CREB binding protein (CBP) 
B Mutant Htt disrupts or its fragments probably bind to the transcriptional factors which result in 
the regulation of gene transcription.  
 
P
CRE
CREB
CBP
Huntingtin
Encephalin
Transcription
Pol II
Transcription 
factors
CRE
CREB
CBP
P Repression
Pol II
Encephalin
Transcription 
factors
Mutant 
Huntingtin
10 
 
2.1.2 Peroxisome proliferator-activated receptor-γ coactivator 1α   
 
Mitochondrial dysfunction and oxidative damage has been considered to be the prime cause for 
neuronal loss. Reactive oxygen species (ROS) are generated primarily in the mitochondria 
during the various metabolic processes in the sub cellular organelles. The ROS are removed from 
the mitochondria by the free radical scavengers found on the inner mitochondrial membrane. The 
enzymatic removal of ROS occurs by Superoxide Dismutase (SOD).  Once there is an imbalance 
created in the production of ROS and their clearance there is oxidative damage and that impacts 
the cell negatively. The cause of the neuronal loss due to oxidative damage is still being 
elucidated. Is it the toxicity that causes the mitochondrial defects or vice versa is still under 
debate (80,81).  
PGC-1α (Peroxisome proliferator-activated receptor-γ coactivator 1α) is involved in energy 
homeostasis, adaptive thermogenesis, glucose metabolism and alpha oxidation of fatty acids.  
The tissues which have high energy needs, express increased levels of PGC-1α and PGC-1β, a 
close homolog (61,64). PGC-1α forms a link between external physiological factors and 
mitochondrial biogenesis. PGC-1α is activated by ROS, CREB and Akt and also regulates the 
activities of CREB (82). 
Transcriptional coregulators are protein interacting with transcriptional factors. This activates or 
represses the function of transcribing genes. A coactivator activates, while co repressors repress 
the gene function. Htt interacts with many transcriptional factors which include CREB, and 
PGC-1α acts as a coactivator (62). PGC-1α deficient mice show HD like symptoms which are 
striatal degeneration and hyperkinetic movements (63). The striatal cell lines, transgenic HD 
mouse models and postmortem brain tissue from HD, all show a diminished PGC-1α function 
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(63). Reduction in the levels of PGC-1α leads to improper energy metabolism and PGC-1α 
knockout mice show striatal degeneration. (82). In HD there is an oxidative damage which 
affects the striatal neurons and PGC-1α protects the neurons against ROS (82). This indicates 
that energy metabolism, ROS defense and neurodegeneration appear to be controlled by PGC-1α 
(64, 65). The knockout mice for PGC-1α show lesions in the brain and most predominantly in 
the striatum. These mice showed impaired thermoregulation and were hyperactive with constant 
limb clasping (68). This shows that PGC-1α plays a major role in the HD pathology because 
striatal degeneration is specific to HD and metabolic abnormalities are also observed in it (82).  
PGC-1α has been shown to be involved in oxidative stress (Fig 11). It reduces the level of ROS 
and also enhances ROS scavenging enzymes (69, 70).  
PGC-1α mRNA has also been shown to be reduced in HD striatal cell lines, HD knock in mouse 
models and HD patients (82). It has been shown that mutant Htt interferes with the transcription 
of the gene encoding PGC-1α (65). Since the expression of PGC-1α was reduced in the medium 
spiny neuron they were vulnerable to degeneration in HD. When a lentiviral vector expressing 
PGC-1α was used to overexpress it in the striatum then neuronal atrophy was prevented in the 
mouse model. Conversely PGC-1α is downregulated the mouse models exhibit behavioral 
neuropathological abnormalities (70,71). There has been a correlation between the transcriptional 
dysregulation and mitochondrial dysfunction in HD and PGC-1α is considered as a key player 
since it is inhibited by mutant Htt (82). Real time PCR data has also shown a decrease in the 
mitochondrial genes in human HD brain thus suggesting that PGC-1α could play a major role in 
the development or progression of HD (71, 72, 73). 
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Figure 4  PGC-1α forms a link between external physiological factors and mitochondrial biogenesis. PGC-1α 
is activated by ROS, CREB and Akt. It also regulates the activities of CREB 
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2.2  Neurotrophins 
 
Neurotrophins or Neurotrophic factors play a role in the growth, survival and differentiation of 
neurons. There is a reduction of these proteins in various neurological disorders; hence they 
seem to play a major role in the maintenance of the neurons. These proteins are secreted proteins 
and include a number of family members. Neurotrophins are transported after they have been 
processed by intracellular pathways. They are initially synthesized as pre / proneurotrophin 
precursors of about 27 kD, after which they are processed and mature neurotrophins of about 
13kD are generated (32, 33). 
They bind to two kinds of membrane receptors found on the plasma membrane. The receptors 
are namely; Tyrosine kinase receptors (Trk) and p75 pan-neurotrophin receptor (p75NTR). A 
number of Trk subtypes have been recognized which are classified according to their affinity to 
bind to various growth factors. Trk A binds to the Nerve growth factor (NGF) sand Trk B allows 
the binding of Brain derived neurotrophic factor (BDNF) and Neurotrophin (NT)-4/5. NT-3 
binds preferentially to TrkC and with lower affinity to Trk B and Trk A (34, 35).  
 
2.2.1 Brain derived Neurotrophic factor 
 
BDNF was discovered in 1982 by Barde et al and his group. It is synthesized from a large 
precursor protein which is 32kD pro-BDNF protein. It moves to the intracellular compartments 
and undergoes proteolytic cleavage and appears in the extracellular compartments after 
maturation as a 14kD protein. Neurotrophins are generally released to the extracellular space 
without any triggers, but it is not the same for BDNF. Its secretion is activity dependent and 
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occurs on receiving depolarizing signals. BDNF can also be secreted as pro-BDNF which later 
undergoes cleavage by extracellular proteinases (76). 
BDNF gene is a highly complex gene regulated by multiple promoters which lead to a complex 
pattern of expression. BDNF is synthesized as a ~32kD precursor protein called pro-BDNF.  It 
forms the biologically active mature form of protein, after cleavage in the trans-golgi apparatus 
or the secretary granules.  
Corticostriatal afferents convey the messages from the cortex to the striatum where it is 
integrated and processed. The corticostriatal synapse is the major site for the release of 
neurotransmitters and any defect at this convergence leads to improper functioning of the brain 
tissue. (76,77). BDNF is expressed in the entire CNS but its levels are higher in the hippocampus 
and the cerebral cortex. From here this neurotrophic factor is transported anterogradely to the 
striatum via the corticostriatal efferents.  
Striatal neurons require BDNF for their health and survival; hence 95% of the striatal BDNF 
comes from the cortex. It has been shown by two groups that some of the BDNF in the striatum 
originates from the substantia nigra and becomes available to the striatal tissue (36). Cortical 
efferents are the primary source of BDNF, was first elucidated by Alter et al in 1997. BDNF has 
been shown to be the major regulator of synaptic plasticity. Its levels have been shown to 
increase during developmental stages. This shows that the factor is important for the normal 
functions of the neurons, its survival and differentiation. (36,77). 
Some groups have co localized Htt and BDNF in the rat cerebral cortex and striatum. BDNF is 
involved in the survival of the striatal neurons that die in HD, therefore making it the molecular 
target for various therapeutic interventions (37, 41). It has been suggested that reduced levels of 
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BDNF play a major role in the onset or progression of HD. Many experimental analyses have 
shown that mutant Htt reduce transcriptional activity of BDNF promoters which leads to reduced 
transcription of the BDNF gene (Fig 6 A,B) (76). The mRNA levels of BDNF were found to be 
reduced in HD striatal samples versus the wild type striatal samples expressing mutant and wild 
type Htt respectively. The production of BDNF protein was more in wild type samples when 
compared to HD striatal samples. A knock in cell line supported the same results which were 
from heterozygous and homozygous mice with 109 CAG triplet repeats. These repeats were 
inserted into the endogenous mouse huntingtin gene (38, 39, 40).  
Transcriptional dysregulation has been shown to be responsible for the reduction in BDNF levels 
in the cortex. The HD brain samples from patients have also revealed the reduction in BDNF in 
the cortex. This was further supported by studies in a huntingtin-knock out mouse, where the 
BDNF levels were shown to be reduced due to absence of wild type Htt protein. This shows that 
the stimulatory function of the wild type Htt is required for the appropriate BDNF levels (41,42). 
BDNF is stimulated at the transcriptional level by different promoters which act independently. 
Wild type Htt is involved in the transcription process and the transcriptional control lies within 
the promoter II (Fig 5A). In the disease the mutant Htt interferes with the transcription of the 
BDNF gene through promoter II (Fig 5B). REST controls the activity of the repressor element 1 
(RE1) within the promoter II. Htt attaches to the REST-interacting LIM domain protein (RILP) 
and prevents REST from binding to RE1. RILP is a cytoplasmic protein, therefore this allows 
REST to be recruited to the cytoplasm. If mutant Htt protein is present then REST is transported 
to the nucleus where it accumulates and binds to the RE1 sites. These RE1 sites are within the 
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BDNF exon II region of the gene, which results in the downregulation of the BDNF gene (40,43, 
44).  
 
2.3 Trk B  
 
BDNF binds to the tyrosine kinase receptor B (TrkB) and leads to the activation of the 
intracellular signaling pathway. The biological activity of BDNF is accomplished when it binds 
to its receptor. TrkB increases in the striatal and cortical neurons after excitotoxic damage and 
mutant Htt reduces the TrkB levels in HD (78). This reduced TrkB level corresponds to the 
mRNA expression in the HD mice. (39,46,78).  
It has been shown that TrkB levels decrease due to mutant Htt and this reduction was associated 
with the decrease in CRE-TrkB promoter activity. This could be inferred as reduced CREB 
mediated transcription might lead to lower expression of TrkB expression in HD cell lines. 
Therefore in neurodegenerative disease where TrkB levels are decreased it will affect the BDNF 
– TrkB interaction which eventually affects the prosurvival signaling pathways (40,45, 47,78).  
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B 
Figure 5 BDNF gene is a highly complex gene regulated by multiple promoters which lead to a complex 
pattern of expression. 
A Wild type Htt is involved in the transcription process and the transcriptional control lies within 
the promoter II 
B Mutant Htt interferes with the transcription of the BDNF gene through promoter II 
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2.4 The cell survival signaling pathway 
 
Akt (also known as Protein Kinase B; PKB) is a potent pro-survival kinase which is involved in 
a number of cellular processes, including mitogenesis, cell size and survival. This serine 
threonine kinase is involved in the cell survival signaling pathway and this is mediated by 
phosphorylating other substrates and enhancing the survival effects in the neurons (48).  The 
pathway is affected in neurodegenerative disorders including HD.  Htt is phosphorylated on Ser-
421 (S421) by Akt and this protects it against the toxicity of the mutant Htt with the poly Q in 
vitro (49).  
Phospho Akt is found in the nuclear inclusion of the HD mice while Akt localizes it the 
cytoplasm (48). Phospho Akt is downregulated in rat striatum of N171-82Q HD rat models. 
Postmortem brain samples of HD patients have also shown a decrease in the activated form of 
Akt (48).  If there is a decrease it the levels of Akt / Phospho Akt then the survival pathway is 
not activated which leads to the increased toxicity of the mutant Htt in the cell (50).  
Apart from the activation of the survival pathway, Akt is involved in the variety of other roles in 
the central nervous system, which includes axon elongation, branching of sensory neurons, 
modulation of synaptic plasticity and many others. Since Akt is involved in many other 
pathways; that require transcriptional regulation, cell proliferation and apoptosis; it plays an 
important role in the neurodegenerative disorders (50, 51).  
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2.5 Molecular chaperones in HD 
 
2.5.1 Heat Shock Factor 1  
 
Heat Shock Factor 1 (HSF 1) is a transcription factor which binds to the heat shock elements 
(HSE) of Hsp genes and causes induction of Hsp proteins under stress conditions (Fig 7). Under 
stress conditions HSF 1 is dissociated from Hsp’s and forms a trimer before its translocation into 
the nucleus. HSF1 is phosphorylated at multiple sites and binds to the heat shock elements (HSE) 
on the promoter region of the target genes (52,79). HSF1 is a master regulator of cell survival 
under stress conditions. The function of HSF1 is regulated by may unknown genes among which 
the known are the Hsp family of genes. HSF 1 also regulates growth factors genes which makes 
it the regulator of various physiologic processes. The tissues containing polyglutamine 
expansions, when over expressed with HSF1 show an attenuation of the disease process (52, 54).  
The expression of HSF 1 in non neural tissues also leads to an increase in the survival of HD 
mice. Chromatin immunoprecipitation has shown that HSF1 binds to a large number of human 
genes in vivo. The binding takes place even under normal conditions, the gene need not be 
induced by stress to bind (52).   
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2.5.2 Heat Shock Protein  70 / 40  
 
Heat Shock Proteins (Hsp) are molecular chaperones that play a major role in protein 
homeostasis (proteostasis) (Fig 8). Proteostasis is a process which ensures that the cells express 
properly folded proteins. The protein homeostasis machinery comes into play and the proteins 
are properly expressed, folded and removed to prevent the cells from the toxic effects of 
misfolded proteins. Molecular chaperones help in proteostasis and prevent the accumulation of 
the misfolded proteins. They are highly conserved and ubiquitously expressed proteins. They are 
found in all subcellular compartments under normal and stressed conditions. The expression of 
molecular chaperones is regulated by various stresses. Stress induced molecular chaperones are 
called Heat shock proteins (Hsps) and their gene families are classified according to their 
molecular mass as Hsp 100, Hsp90, Hsp 70, Hsp 60, Hsp 40 and small Hsps (sHsps). Cells show 
an increase in the heat shock response under stress conditions and survive. If the cells are unable 
to induce enough heat shock proteins they succumb to stress and die. There is cascade of events 
start with the activation of the heat shock proteins by HSF1 (52,79).  
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There are various types of stresses which can affect a cell. They are i) environmental stress such 
as temperature change ii) chemical stress such as ROS iii) pathophysiological states causing 
stress such as bacterial, viral infection etc.  The cell expresses Hsps, genes encoding chaperones 
and other proteins to reduce the effect of stress and maintain the proteasomal homeostasis. 
Proteasomes are very large complex protein complexes involved in the regulation of misfolded 
proteins. The lysis of these proteasomes is carried out by proteases, termed proteolysis. In 
diseased conditions like HD either the proteosomal machinery is exhausted in clearing up or the 
aggregation of the protein escapes the misfolded protein degradation machinery and toxic protein 
affects the cellular functions (55).  
The poly Q expansion in HD acts as a stress factor which leads to the protective stress response 
in the form of upregulation of Hsps. (53). Hsps have been shown to reduce poly Q aggregation 
(55). Since HSPs are molecular chaperones and they protect the cells by preventing misfolding 
and / or aggregation they protect against neurodegeneration caused by poly Q expansion. 
Therefore Hsps help in maintaining normal protein structure and function (79). 
Hsps are highly conserved between different species. Most of these proteins donot act alone but 
form complexes consisting of an Hsp and a co-chaperone. Co-chaperones are proteins that 
modulate the activity of primary chaperones (57). In humans there are about eleven genes 
encoding Hsp 70, all having a conserved N-terminal ATPase domain and a C-terminal substrate 
binding domain.  Hsp 40 binds to Hsp 70 and promotes ATP hydrolysis and acts as a 
conformational switch to allow its interaction with nonnative substrates (58) (Fig 6).   
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Toxicity in HD results due to the presence of mutant Htt. The misfolded proteins accumulate in 
the cytoplasm as aggregates which might disrupt the ubiquitin-prtoteasome system (UPS). If the 
UPS is disrupted there is increase in the misfolded proteins in the cytoplasm (52,59). In HD 
mouse models endogenous Hsp 70 has shown to alleviate the symptoms of the disease, which 
has been confirmed by behavioral tests (52,57). In these mouse models the presence of Hsp 70 
acts as a protective mechanism, protecting the cell to the toxic effects of mutant Htt.  Hsp 70 has 
been shown to regulate the toxicity of the mutant Htt in the mouse model of HD. Hsp 70 and Hsp 
40 interact with Htt by stabilizing the mutant protein. They suppress the accumulation of annular 
and spherical oligomeric forms of mutant Htt. Based on this; the primary function of Hsp 70 in 
HD is to prevent the formation of toxic monomers and oligomers. It is assumed that Hsp’s also 
prevent the interaction of mutant Htt with the cellular components which are involved in the 
physiological processes in a cell (58, 60).  
 
 
 
 
 
 
 
Figure 6 Hsps regulate the cellular processes by modulating the misfolded protein and prevent stalling of the 
normal physiologic function and thereby reducing the toxic effects of the mutant protein. 
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2.6 Depression and HD 
 
Depression is the most common psychiatric symptom that is observed in HD patients. Patients 
suffering from depression need symptomatic treatment which is mostly in the form of drugs 
which have a number of harmful side effects. Patients with HD are more likely to commit suicide 
compared to the population suffering from a mental disorder (110). Suicidal tendency was 
highest among the gene carriers who were at the threshold of being diagnosed with HD (113). 
The suicidal thoughts have been linked to the patients losing their ability to function 
independently as well as to depression leading to suicidal thoughts. The patients need special 
attention and a check needs to be performed to see if they are developing suicidal tendencies. A 
number of neurological problems involving the patient undergoing chronic depression which 
remains untreated with drugs led to the introduction of ECS for the treatment of drug resistant 
depression (74,85). Various neurodegenerative diseases have been correlated with dementia and 
increased suicide rates. There seems to be an association between dementia and suicide. There 
are functional impairments which lead to the inability to think and plan which leads to self 
destructive acts (87, 88). Suicidal tendencies have been noticed in patients suffering with 
Alzheimers disease (92). Dementia is also seen in about 60% of the patients with Parkinson 
disease (93).  
HD patients show neurological symptoms before they show any signs of dementia. The attempt 
to suicide and suicidal deaths were four times the normal general population in HD patients. The 
deaths have been shown to occur at an early stage of the disease and hence if treated early could 
reduce the suffering of the patients as well as improve the lifestyle of the individual. Since HD is 
a genetic disorder it can be detected at an early stage if an individual is predisposed to it. A 
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treatment to alleviate the symptoms of dementia and depression could be beneficial to improve 
the quality of life of the patients suffering. (92, 93, 94, 95).  
 
2.7 Electroconvulsive shock (ECS) 
 
Electroconvulsive shock (ECS) is defined as a medical procedure in which a brief electrical 
stimulus of variable frequency applied to the scalp via electrodes is used to induce a cerebral 
seizure (134). Historically, ECS has been used mainly to treat depressive disorders since 1938 
(134,135). Development of key psychotropic drugs one after another in the mid-20th century 
opened a revolutionary era of modern psychopharmacology, which made ECS relatively 
unpopular. However the presence of drug-resistant depression has necessitated the revival of 
ECS. ECS has become indispensable choice for the severest form of depression than any other 
forms of treatment (136). A recent review that pools data from 26 studies that result in an 
increase in global improvement for people with schizophrenia (137). The antidepressant effect is 
reliable and can persist more than a year (137). ECS has improved the quality of life for nearly 
80% of patients. Suicide attempts are relatively rare after ECS.  
The science of ECS has progressed rapidly over the last 20 years (134,138, 139,140,141,142). 
ECS uses precisely calculated electrical currents administered in a controlled setting to achieve 
the most benefit with the fewest possible risks (134,141,142). Numerous studies have 
demonstrated the safety and efficacy of ECS for various psychiatric conditions, and it has been 
approved by the Food and Drug Administration for the treatment of refractory depression. The 
American Psychiatric task force identifies no absolute contradictions and approves ECS as “safe 
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and effective” treatment for psychiatric disorders including depressive illness, schizophrenia, 
catonia and mania (135).Responsiveness to ECS does not abate with age which is a major risk 
factor in many neurological disorders. Despite an increasing body of evidence that ECS is 
effective, safe and has no detrimental effects, its dissemination appears still limited 
(136,138,139,141,143). One reason may be its public misconceptions, knowledge, and inaccurate 
depictions (144,145). Another reason may be that its neurobiological mechanisms are far from 
elucidated. It is hoped that once the biological benefits of ECS is understood in depth, a less 
invasive alternative, or a pharmaceutical or gene-technological replacement might be developed. 
Apart from its use in psychiatry ECS has been reported to have therapeutic benefits for the 
treatment of certain neurological conditions independent of its psychiatric effect (146). These 
include Parkinson’s disease, neuroleptic malignment syndrome, and aggressive behavioral 
disorders following brain injury, certain forms of epilepsy, and some forms of delirium due to 
toxic metabolic encephalopathies (134).  
ECS was initially given in a sinusoidal waveform, which is less efficient. The electrical impulse 
provided is below the depolarization threshold of the neurons and hence produces no significant 
changes in the patient. The brief pulse stimulus was introduced later which allows the delivery of 
full current amplitude instantaneously thus making the procedure efficient. ECS was initially 
delivered bilaterally which later was changed to the unilateral way. Since both the ways did not 
show significant difference the bilateral electrode placement was restored.  
Neuroplasticity has an important role to play in the recovery from depression (74). 
Antidepressant drugs and electroconvulsive shock has been shown to elevate the levels of 
neurotrophins. This includes BDNF and its receptor Trk B, which increase the neurogenesis and 
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the number of synapses in the different brain regions. This indicates neuronal plasticity may be 
able to alleviate the depression and BDNF can play a major role in the rewiring of the 
dysfunctional neuronal network. It has been shown that ECS is the most efficient and safe 
treatment against depression. It leads to an increase in the BDNF mRNA within minutes to hours 
of treatment (74,84). BDNF is responsible for the growth and survival of the neurons and has 
been shown to increase after ECS treatment (84, 86). ECS induces a number of complex brain 
events which can be broadly classified as intracellular signal transduction and regulation of 
gene expression. Intracellular signal transduction is a process which converts a chemical / 
mechanical stimulus to the receptor into a specific cellular response. This response creates a 
change in the cell within the cytoplasmic compartment or the nucleus. The regulation of the 
information contained in the genes to convert them into gene products is termed as regulation of 
gene expression. This gene expression is modulated by transcription or by post-translational 
modification of a protein. These signaling mechanisms and regulation of the gene expression by 
ECS produces a significant change in the condition of patients suffering from depressive 
disorders; as mentioned above; by an upregulation of neurotrophic factors such as BDNF 
(84,89,90).  
ECS can lead to rapid and significant improvements in symptoms compared to psychotherapy or 
medication, it should be considered as a treatment in the management of depression in patients 
with HD, eventually contributing to decrement of the number of depression-driven suicides 
(147,148,149,150). The America Psychiatric Association recommends that ECS could be 
delivered to patients who respond to the treatment and are drug resistant otherwise (87,91) The 
reduction in depression is correlated with an increase in BDNF, which has been shown to be 
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neuroprotective. Thus ECS could be neurorestorative in HD patients along with alleviating 
depression. Hence it could be an efficient supportive therapy in improving the conditions of HD 
patients and attenuate the disease condition. 
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CHAPTER 3. MATERIALS AND METHODS 
3.1 Mice and Electroconvulsive Shock Treatment 
 
HD-N171-82Q mice were purchased from the Jackson Laboratories (Bar Harbor, ME) and were 
maintained on the B6C3F1 background; offspring were identified by PCR analysis using 
genomic DNA extracted from tail biopsies to distinguish transgene-bearing mice from their wild 
type littermates (95). Mice were maintained under usual laboratory conditions that included ad 
libitum feeding and drinking, in a non enriched environment (96). Experiments were performed 
on 2 month old male mice that were assigned randomly to control and ECS treatment groups. All 
procedures were approved by the National Institute on Aging Animal Care and Use Committee. 
ECS was delivered to anesthetized mice once a week via bilateral ear clip electrodes using the 
Ugo Basile, ECT Unit 7801. The stimulus current was 50 mA and the stimulus duration was 
0.2s. The presence of seizures immediately after the shock was confirmed by observing the 
extension of all limbs and forward head extension that normally last for 10-15 s. The sham 
groups were handled identically to the ECS-treated animals except no current was applied. ECS- 
and sham-treated mice were returned to their cages 10 min afterwards (Fig 7) 
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Figure 7 ECS was delivered to anesthetized mice once a week via bilateral ear clip electrodes using the Ugo 
Basile, ECT Unit 7801. 
3.2 Rotarod Test 
 
Motor coordination and balance were evaluated using an accelerating rotary rod apparatus 
(Columbus Instrument, OH) as described previously (97). Mice were trained to use the rotarod 
apparatus during a 2 min trial (4 rpm) on the day before the first day of testing. On test days, 
mice were placed on the rotarod for three trials for a maximal 4min at accelerating speeds from 
440rpm and maintenance at 40 rpm after 4 min. Each trial was separated by a 30 min rest period 
to alleviate stress and fatigue. The rotarod tests were conducted weekly to follow the progression 
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of the disease process; latency to fall and falling times for each mouse were recorded by a trained 
observer blind to the treatment group of the mice. 
 
3.3 Survival Study 
 
Once motor symptoms appeared the HD mice were examined twice daily in the early morning 
and late afternoon. Mice unable to right themselves after being placed on their backs and unable 
to initiate movement after being gently prodded for 30s were euthanized; their age at this point 
was considered the age of death. Deaths that occurred overnight were recorded the next morning. 
 
3.4 Immunohistochemistry 
 
Immediately after being anesthetized with an overdose of isoflurane, mice were perfused 
transcardially with saline, followed by 4% paraformaldehyde (PFA) in PBS (pH 7.4). Brains 
were post-fixed in 4% PFA for 24 h, and then cryoprotected in 30% sucrose/PBS for 48 h. Serial 
coronal sections (10 µm thickness) cut through the entire striatum with a freezing microtome 
(Microm HM 505 N) were collected on slides. Sections were blocked with 5% normal serum in 
0.1% Triton X-100 in PBS for 30min at room temperature followed by incubation overnight at 
4oC with primary antibodies against N-terminal Htt (EM48, Chemicon; 1:400 dilution) and 
NeuN (Chemicon; 1:400 dilution). Tissue sections were incubated with Alexa568- or Alexa488-
conjugated secondary antibodies (1:200, Molecular Probes) appropriate for the specific primary 
antibodies. The sections were then washed with 0.05% Tween-20 in phosphate-buffered saline 
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for 1h and counterstained with 4'6'-diamidino-2-phenylindole (DAPI) (50ng/ml) for 30s, washed, 
and mounted in FluorSave medium (Calbiochem). Additional sections were stained with Fluoro 
Jade C (98). 
 
3.5 Quantification of Htt Aggregates and Damaged Neurons 
 
Images of EM48-positive neuronal inclusions and Fluoro Jade C-positive neurons were obtained 
by scanning 1012 coronal sections spread over the anterior - posterior extent of the striatum 
(inter-section distance: 400 m), using a 20 objective on a Nikon 80i Research Upright 
Microscope equipped with image acquisition software (Qimaging Retiga 2000). All images were 
segmented using the same light threshold, mask smoothing and object size filters. Total area of 
pixel intensity was measured with the automated measurement tools in IP lab software (BD 
Biosciences- Bio-imaging). The total density was averaged and expressed as normalized, 
corrected OD. All brain specimens were coded and analyses were performed by an investigator 
blinded as to the genotype and treatment group of the mice. 
 
3.6 Immunoblotting 
 
Protein quantification, electrophoretic separation and transfer to nitrocellulose membranes were 
were performed. Membranes were incubated in blocking solution (5% milk in Tween Tris 
Buffered Saline; TTBS) overnight at 4oC followed by a1 h incubation in primary antibody 
diluted in blocking solution at room temperature. Membranes were then incubated for 1 h in 
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secondary antibody conjugated to horseradish peroxidase (Vector Laboratories) and bands were 
visualized using a chemiluminiscence detection kit (ECL, Amersham). Membranes were stripped 
and re-probed with the actin antibody to verify and normalize protein loading (50 µg total 
protein, unless stated otherwise). For immunodetection of blots, enhanced chemiluminescence 
(ECL, Amersham) was applied. Immunoreactive bands were quantified using NIH Image 
software. Information on the primary antibodies used in this study, including the source, dilution 
and molecular weight of the antigen can be found in Table 1. 
Table 1 Primary Antibodies Used in the Study 
Primary 
Antibody 
Secondary 
Antibody 
Dilution Company Mol wt 
     
CREB Rabbit mAb 1:1000 Cell Signaling 43 kD 
pCREB Rabbit mAb 1:1000 Cell Signaling 43 kD 
Akt Rabbit pAb 1:800 Cell Signaling 60kD 
pAkt Rabbit mAb 1:800 Cell Signaling 60kD 
Hsp 70 Mouse mAb 1:1500 Abcam 70-78kD 
Hsp 40 Rabbit pAb 1:1500 Abcam 40kD 
Hsf1 Rabbit pAb 1:500 Abcam 83kD 
BDNF Rabbit pAb 1:1000 Santa Cruz <20kD 
PGC1 ∞ Rabbit pAb 1:5000 Santa Cruz 85-90kD 
 
 
3.7 Statistical analysis 
 
Kaplan-Meier survival data was analyzed using log-rank test for trend. All other data were 
analyzed using one-way ANOVA with Dunnetts post-hoc test for pairwise comparisons or 
Students t-test as appropriate. These statistical analyses were performed using GraphPad Prism 
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version 5.00 for Windows (GraphPad Software, San Diego, CA). p values < 0.05 were 
considered significant. 
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CHAPTER 4. RESULTS 
 
Electroconvulsive shock ameliorates motor deficits and improves survival of HD-N171-82Q 
mice Previous studies showed that N171-82Q HD mice have an abbreviated life span of about 
21-22 weeks and exhibit motor deficits beginning at 14-16 weeks of age (95). To determine 
whether ECS provides significant clinical benefits in an animal model, we assessed the impact of 
ECS on the development of behavioral symptoms, and on the survival, of male HD-N171-82Q 
HD mice. Beginning at 2 months of age, 20 wild-type and 20 HD mice were randomly assigned 
to either an ECS treatment group or a sham control group (10 HD and 10 wild-type mice per 
group); ECS was administered once weekly. HD mice in the ECS group lived significantly 
longer, by an average of 2 weeks, than did HD mice in the sham control group (Fig. 13A). No 
wild-type mice in either ECS or sham groups died during the 200 day course of this study. ECS 
also prevented the progressive weight loss that occurred in sham-treated control HD mice (Fig. 
13 B). To determine the impact of ECS on motor function, we subjected 14 week-old mice to 
rotarod testing. We found that latency (time until falling) was significantly greater and the 
frequency of falling was significantly less in ECS-treated compared to sham-treated HD mice 
(Fig. 13C,D). Collectively, these data demonstrate that ECS treatment ameliorates the behavioral 
deficits and extends the survival of HD mice. 
4.1 ECS ameliorates striatal degeneration 
 
To determine whether improved motor function and improved survival of HD mice treated with 
ECS results from a slowed progression of the neurodegenerative process, we performed 
histological analyses to evaluate neuronal degeneration in the striatum in brain tissue sections 
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from ECS- and sham-treated HD and wild-type mice that were killed at 16 weeks of age (an 
early symptomatic time point). In HD-N171-82Q mice, neuronal loss occurs primarily in the 
striatum and cerebral cortex resulting in a corresponding enlargement of the lateral ventricles 
(95,96). Degenerating neurons in HD-N171-82Q mice are found predominantly in both cortex 
and striatum beginning at approximately 14 weeks of age (95), and so we evaluated neuronal 
degeneration at 16 weeks of age when neurodegeneration is prominent. The number of Flouro 
Jade C-labeled degenerating striatal cells was significantly lower in ECS-treated HD mice 
compared to sham-treated control HD mice (Fig. 14A). The number of NeuN-labeled neurons 
was significantly greater in the striatum of ECS-treated HD mice compared to control HD mice 
(Fig. 14B). Progressive striatal and cortical atrophy results in bilateral ventricular enlargement 
and flattening of the medial aspect of the striatum, accompanied by thinning of the cerebral 
cortex in HD mice (10). As expected, the lateral ventricle size in 16 week-old sham control HD 
mice was significantly greater than that of age-matched wild type mice (Fig. 14C). In contrast, 
the ventricles of 16 week-old ECS treated HD mice were significantly smaller than the ventricles 
of control HD mice, and similar in size to wild-type mice (Fig. 14C). These findings suggest that 
ECS protects striatal and cortical neurons against the neurodegenerative effects of mutant Htt. 
 
4.2 ECS reduces Htt protein aggregation 
 
Mutant Htt forms abnormal intracellular aggregates in degenerating neurons in the striatum and 
cortex of HD mice (96-99), and Htt aggregates are associated with neuronal dysfunction and 
death (100). We therefore determined whether ECS reduced neuronal degeneration by 
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suppressing Htt aggregate formation or by protecting neurons downstream of Htt aggregate 
formation. The density of Htt aggregates in the striatum, as measured by image analysis of brain 
sections immunostained with an Htt antibody, was significantly lower in ECS treated HD mice 
compared to sham control HD mice (Fig. 14D). No Htt immunoreactivity was detected in brain 
sections from wild-type mice. 
 
4.3 ECS restores BDNF levels in the striatum of HD mice 
 
The transcription of the bdnf gene has been reported to be impeded by mutant Htt protein, and 
BDNF protein levels are reduced in the striatum of HD patients and Htt mutant mice 
(96,99,100,101). ECS can increase BDNF levels acutely (within minutes to a few hours) in the 
hippocampus and cerebral cortex of normal mice, and this effect of ECS is potentiated by prior 
ECS treatments (102). We therefore determined the effects of ECS on BDNF levels in the 
striatum of HD mice. For these and subsequent biochemical and immunohistochemical analyses 
the mice were given a final ECS or sham treatment at 13 weeks of age, and were sacrificed 1 
week later. BDNF protein levels, measured by both immunoblot (Fig. 17A) and ELISA (Fig. 
17B) analyses, were significantly lower in the striatum of HD mice compared to wild-type mice. 
BDNF levels were significantly greater in ECS-treated HD mice compared to sham-treated HD 
mice (Fig. 17A, B). We next measured striatal levels of activated (phosphorylated) Akt and 
CREB, a kinase and transcription factor involved in BDNF signaling and BDNF transcription 
induction, respectively. The levels of p-Akt and p-CREB were significantly lower in the striatum 
of sham-treated HD mice compared to wild-type mice (Fig. 19). In contrast, levels of p-Akt and 
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p-CREB were similar in the striatum of ECS-treated HD mice and wild-type mice (Fig. 19), 
suggesting that ECS can prevent the impairment of Akt- and CREB mediated signaling caused 
by mutant Htt. 
 
4.4 ECS normalizes levels of heat shock proteins in the striatum of HD mice 
 
Heat-shock proteins (Hsps) are protein chaperones that prevent misfolding and aggregation of 
newly synthesized mutant proteins and damaged normal proteins. Recent findings suggest that 
levels of several Hsps decrease in striatal neurons in HD, possibly as the result of sequestration 
of mutant Htt (103,104). Additional findings suggest that mutant Htt can sequester heat-shock 
factor 1 (HSF1), a transcription factor responsible for the induction of many Hsps (105). To 
determine whether reduced aggregation may be attributed to increased expression of Hsps, we 
performed immunoblotting of striatal and cortical homogenates from HD-N171-82Q and wild-
type mice treated with ECS or sham. ECS treatment markedly increased the level of Hsp70 and 
Hsp40 protein in HD mice (Fig. 20A). The increase of Hsps was associated with an increased in 
HSF1 protein (Fig. 20B). These results suggest that ECS increases expression of Hsps in HD 
mice via a mechanism that may be dependent on HSF1. 
 
4.5 ECS increases levels of PGC-1α 
 
Previous findings suggest that mitochondrial dysfunction plays a role in the pathogenesis of HD, 
possibly as a result of interactions of mutant Htt with the outer mitochondrial membrane leading 
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to perturbed mitochondrial calcium handling and impaired energy production (106,107).  
Emerging findings suggest that the transcriptional co-activator PGC1-α plays major roles in 
regulating mitochondrial biogenesis, function and vulnerability to stress (108). Consistent with a 
previous report (109), we found that levels of PGC1-α were significantly lower in the striatum of 
HD mice compared to wild-type mice (Fig. 22). ECS-treatment resulted in a significant 
preservation of PGC1-α levels in HD mice. There was a trend towards increased PGC1-α levels 
in ECS-treated wild-type mice (Fig. 22). Collectively, these findings suggest that that ECS may 
up-regulate multiple adaptive cellular stress response proteins to protect striatal neurons against 
pathogenic actions of mutant Htt. 
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Figure 8 Electroconvulsive shock treatment ameliorates motor deficits and extends survival of HD mice. 
A. HD-N171-82Q HD mice were treated once weekly with either ECS (n = 10) or sham control 
(n = 10) beginning at beginning at 2 months of age and deaths were recorded. The Kaplan-Meier 
analysis revealed a significantly greater survival of mice in the ECS group (p<0.05). B. Body 
weights of wild-type (WT) and HD mice in the ECS or sham control (CTL) groups. C and D. 
Results of rotarod analysis of motor function (14 week-old mice) showing falling latency (C) and 
number of falls (D) for WT and HD mice in the CTL and ECS treatment groups. Values are the 
mean and SEM (n = 10 mice per group). *p < 0.05, **p<0.01. 
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Figure 9 ECS treatment attenuates the degeneration of striatal neurons in HD mice. 
A. Images of FluorJade C (FJ-C)-stained cells (upper micrographs; scalebar = 250 µm) and 
results of counts of FJ-C stained cells (lower graph) in 16 week-old WT and HD mice in ECS or 
sham control treatment groups. B. Images of NeuN-stained cells (upper micrographs; scale bar = 
250 µm) and results of counts of NeuN-positive cells (lower graph) in 16 week-old WT and HD 
mice in ECS or sham control treatment groups. 
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Figure 10 Images of cresyl violet stained coronal brain sections 
Images of cresyl violet stained coronal brain sections (upper micrographs) and results of 
measurements of the area of the lateral ventricle (lower graph) in 16 week-old WT and HD mice 
in ECS or sham control treatment groups. Scale bar = 250 µm. 
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Figure 11 Images showing huntingtin (Htt) immunoreactive aggregates 
Images showing huntingtin (Htt) immunoreactive aggregates (red; upper micrographs; scale bar 
= 250 µm) and results of densitometric analysis of Htt immunoreactivity (lower graph) in 16 
week-old HD mice in ECS or sham control treatment groups. Values are the mean and SEM (n = 
9-10 mice per group). *p<0.05, **p<0.01, ***p<0.001 
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Figure 12 ECS ameliorates deficits in levels of BDNF, and activated Akt and CREB, in the striatum of HD 
mice. 
 A. A representative immunoblot (left) andresults of densitometric analysis of BDNF protein 
levels in striatal tissue samples from ECS-treated and control (C) HD and WT mice. B. BDNF 
protein levels, measured by ELISA analysis, in samples of striatal tissue from ECS treated and 
control HD and WT mice. C. A representative immunoblot (upper) and results of densitometric 
analysis of phospho-Akt protein levels in striatal tissue samples from ECS-treated and control 
(C) HD and WT mice. D. A representative immunoblot (upper) and results of densitometric 
analysis of phospho-CREB protein levels in striatal tissue samples from ECS-treated and control 
(C) HD and WT mice. Values are the mean and SEM (n = 8-10 mice per group). *p<0.05, 
**p<0.01, ***p<0.001  
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Figure 13 Levels of BDNF is elevated in striatal cells of HD mice treated with ECS. 
Levels of BDNF are elevated in striatal cells of HD mice treated with ECS. Images showing 
BDNF (red in micrographs at right) and results of densitometric analysis of immunoreactivities 
(graphs) in 16 week-old HD mice in ECS or sham control treatment groups. Values are the mean 
and SEM (n = 10 mice per group). **p<0.01, ***p<0.001. Scale bar = 20 micrometers. 
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Figure 14 Levels of pAkt elevated in striatal cells of HD mice treated with ECS. 
Levels of pAkt elevated in striatal cells of HD mice treated with ECS. Images showing pAkt (red 
in micrographs at right) and results of densitometric analysis of immunoreactivities (graphs) in 
16 week-old HD mice in ECS or sham control treatment groups. Values are the mean and SEM 
(n = 10 mice per group). **p<0.01, ***p<0.001. Scale bar = 20 micrometers. 
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Figure 15 ECS elevates levels of adaptive stress response proteins in the striatum of HD mice. 
ECS elevates levels of adaptive stress response proteins in the striatum of HD mice. A 
representative immunoblot (left) and results of densitometric analysis of HSP 70 and HSP 40 
protein levels in striatal tissue samples from ECS-treated and control (C) HD and WT mice. B. 
An immunoblot (left) and results of densitometric analysis of HSF-1 protein levels in striatal 
tissue samples from the indicated groups of mice. Values are the mean and SEM (n = 8-10 mice 
per group). *p<0.05. 
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Figure 16 Levels of protein chaperones are elevated in striatal cells of HD mice treated with ECS. 
Levels of protein chaperones are elevated in striatal cells of HD mice treated with ECS. Images 
showing HSP70 and  HSP40 (red in micrographs at right) and results of densitometric analysis of 
immunoreactivities (graphs) in 16 week-old HD mice in ECS or sham control treatment groups. 
Values are the mean and SEM (n = 10 mice per group). **p<0.01, ***p<0.001. Scale bar = 20 
micrometers. 
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Figure 17 Levels of PGC-1α are reduced in the striatum of HD mice, and are partially or fully restored by 
ECS treatment. 
Levels of PGC-1α are reduced in the striatum of HD mice, and are partially or fully restored by 
ECS treatment. Immunoblots (upper) and results of densitometric analysis (lower) of protein 
levels of PGC-1 α (C) in striatal tissue samples from the indicated groups of mice. Values are the 
mean and SEM (n = 8-10 mice per group). *p<0.05, **p<0.01, ***p<0.001. 
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CHAPTER 5. CONCLUSION 
 
Once-weekly ECS treatments delayed disease onset and extended survival in Htt mutant mice. 
Biochemical and histological analyses demonstrated a reduction in neuronal degeneration, and 
elevated levels of neuroprotective proteins (BDNF, protein chaperones and PGC1α) in the 
striatum of ECS-treated HD mice compared to sham-treated HD mice. These results in an animal 
model of HD suggest that ECS can counteract the pathogenic actions of mutant Htt, thereby 
preserving the viability and function of striatal neurons. There have been several reports 
describing beneficial effects of ECS in relieving depression in HD patients (110,111,112), and in 
some cases motor symptoms also abated (113). However, there have been no controlled studies 
of ECS treatment in symptomatic HD patients, nor any attempts to delay the onset of HD with 
periodic ECS treatments.  
BDNF plays critical roles in synaptic plasticity and neuronal survival in many brain regions 
including those affected in HD. Previous studies have shown that endogenous BDNF (117) and 
BDNF delivered directly or by transgenesis (114-116), can protect striatal and cortical neurons in 
experimental models of HD. We found that striatal BDNF levels were reduced in HD compared 
to wild-type mice, and that BDNF levels were significantly increased in HD mice that had been 
maintained on long-term ECS treatment compared to sham control HD mice. The elevation of 
BDNF levels may mediate, at least in part, the retardation of disease onset and extension of 
survival by ECS in the HD mice. Consistent with the latter possibility, it was reported that 
paroxetine and seratraline, two other anti-depressant treatments that increase BDNF levels in the 
striatum and cortex, also delay disease onset and extend survival in HD mice (118-119). BDNF 
may protect neurons against excitotoxic, metabolic and oxidative stress believed to be involved 
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in the death of neurons in HD. Indeed, BDNF can protect neurons against glutamate receptor-
mediated excitotoxicity (116,120) energetic/mitochondrial stress (114,115) and oxidative insults 
(121). 
In addition to sustaining BDNF levels, ECS treatment resulted in elevated levels of the protein 
chaperones Hsp70 and Hsp40, and the stress-responsive transcriptional regulator HSF-1, in the 
striatum of HD mice. Studies in which levels of Hsp70 or Hsp40 are selectively increased or 
decreased using molecular genetic technologies have shown that these two proteins can protect 
neurons against insults relevant to HD including excitotoxins, metabolic stress and mutant Htt 
(122,123). Moreover, Hsp70 can preserve electrical activity in striatal neurons subjected to 
mitochondrial stress (124), suggesting the possibility that therapeutic interventions that up-
regulate Hsps may improve motor function in HD patients. 
Mutant Htt causes major perturbations of energy metabolism as indicated by the negative energy 
balance and progressive weight loss of HD patients (125), demonstrated by mitochondrial/energy 
utilization deficits in brain (99) and peripheral (98,99) cells of HD patients, and by the 
dysregulated metabolic state of Htt mutant mice and striatal neurons therein (96,97,130). Recent 
findings suggest that reduced expression and/or impaired function of PGC-1α, which regulates 
mitochondrial biogenesis and function in neurons, plays a role in the abnormalities of cellular 
energy metabolism in HD (131). Thus, it was reported that mutant Htt impairs mitochondrial 
function, in part, by repressing PGC-1α gene transcription (132), and the global metabolic 
abnormalities in HD mice have been linked to perturbed PGC-1α actions (108). In addition, 
levels of PGC-1α target gene expression are reduced in skeletal muscle cells from HD patients 
and Htt mutant mice, and viral delivery of the PGC-1α increased expression of PGC-1α target 
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genes and resistance of HD myofibers to metabolic stress (133). We found that ECS treatment 
significantly attenuated the depletion of PGC-1α from striatal cells in HD mice. Therefore, it is 
likely that maintenance of PGC-1α contributes to process by which ECS treatment preserves 
mitochondrial function and protects neurons against mutant Htt. 
Our preclinical findings demonstrate that ECS treatment counteracts the neurodegenerative 
process caused by mutant Htt in an animal model of HD. There has recently been a resurgence of 
interest in the use of ECS for the treatment of drug-refractive psychiatric disorders, and it is 
considered safe and effective for treatment of depression in the elderly, including those with co-
morbidities (132). ECS treatments often result in long-lasting clinical improvements in 
psychiatric symptoms. We found that ECS treatment resulted in increases in the expression of 
several adaptive cellular stress response proteins (BDNF, Hsp70, Hsp40, and PGC-1α) which 
may promote neuronal survival and plasticity, and so forestall the neurodegenerative process 
resulting in a delay in the disease onset and life extension. 
Neurodegenerative diseases, whether acute or chronic, are a tremendous medical problem it the 
modern world. Therapies are rare and only applied after a vast amount of neurons are lost due to 
the relatively late appearance of symptoms. The difficulty therein is early diagnosis and 
successful neuroprotection by targeting the pathological initiators early enough with effective 
pharmaceuticals to circumvent irreversible neuronal damage. HD is one of the most common 
inherited disorders in which there is progressive neurodegeneration and for which there is no 
cure. Because of strong genetic link and freely available genetic test, preventive therapy could be 
given to individuals who inherit the mutated htt gene and who will, at some stage, develop the 
disease.  The opportunity to administer preventive therapy would maximize the time HD patients 
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spend in the mildest stages of the diseases, lessening movement disturbances and emotional 
cognition for the remainder of his or her lifetime.  
There has been a resurgence of interest in ECS for the treatment of neurological disorders 
because it has evolved into a safe option and one that is effective. Furthermore, responsiveness to 
ECS does not abate with age which is the major risk factor for many neurological disorders. 
Recent studies on the neurobiological mechanisms of ECS reveal the induction of genes and 
molecules that lie at the crossroads of psychiatric and neurological disorders. We found that ECS 
increases the expression of BDNF, HSP70 and potentially other neuroprotective genes in the 
striatum and cortex, the major sites of cell loss in HD brain. The involvement of BDNF in 
cognitive processes and neuroprotection and the impaired BDNF expression reported for HD 
patients suggests that a deficit of this neurotrophin is a logical contributor to memory and 
cognitive problems and brain atrophy associated with the disease. ECS can provide additional 
benefits in the clinical management of psychiatric symptoms in HD patients, many of whom are 
refractory to medical treatment. Our findings provide a rationale for investigating further 
whether ECS could form the basis of an effective strategy to mitigate the neuropathological 
sequelae of gross brain and neuronal atrophy while preventing the development of dementia and 
psychiatric symptoms in individuals at risk for HD. 
For future studies we would determine whether BDNF is essential for the beneficial effects 
induced by ECS, we will perform similar experiments in heterozygous BDNF KO mice. To 
combine ECS with pharmacotherapy to maximize treatment efficacy would be an efficient way 
to extend this therapy to the HD patients. As most existing drug treatments for HD produce only 
partial or moderate effects, we propose that combination treatment with ECS might prove to be a 
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more promising. We propose that combining safe and well-tolerated tricyclic antidepressants 
(TCAs) with ECS would have even greater efficacy and benefits by raising the levels of 
neuroprotective proteins in HD patients.   
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